Log in

NASDAQ:PTEPolarityte Stock Price, Forecast & News

$0.98
-0.03 (-2.98 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.92
Now: $0.98
$1.01
50-Day Range
$0.82
MA: $0.97
$1.15
52-Week Range
$0.78
Now: $0.98
$6.72
Volume452,606 shs
Average Volume623,064 shs
Market Capitalization$37.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTE
CUSIPN/A
CIKN/A
Phone385-237-2279

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.65 million
Book Value$1.08 per share

Profitability

Net Income$-92,490,000.00
Net Margins-1,561.72%

Miscellaneous

Employees153
Market Cap$37.55 million
Next Earnings DateN/A
OptionableOptionable

Receive PTE News and Ratings via Email

Sign-up to receive the latest news and ratings for PTE and its competitors with MarketBeat's FREE daily newsletter.

Polarityte (NASDAQ:PTE) Frequently Asked Questions

How has Polarityte's stock been impacted by COVID-19 (Coronavirus)?

Polarityte's stock was trading at $1.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PTE shares have decreased by 8.7% and is now trading at $0.9764. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Polarityte?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Polarityte.

How were Polarityte's earnings last quarter?

Polarityte Inc (NASDAQ:PTE) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.39) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.18. The business earned $0.93 million during the quarter, compared to the consensus estimate of $1.27 million. Polarityte had a negative net margin of 1,561.72% and a negative return on equity of 157.30%. During the same period in the previous year, the firm earned ($1.18) EPS. View Polarityte's earnings history.

What price target have analysts set for PTE?

5 brokers have issued 12 month price targets for Polarityte's stock. Their forecasts range from $3.00 to $8.00. On average, they expect Polarityte's stock price to reach $5.40 in the next twelve months. This suggests a possible upside of 453.1% from the stock's current price. View analysts' price targets for Polarityte.

Has Polarityte been receiving favorable news coverage?

Media coverage about PTE stock has been trending very negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Polarityte earned a news impact score of -3.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutPolarityte.

Are investors shorting Polarityte?

Polarityte saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 3,090,000 shares, a decrease of 6.4% from the March 31st total of 3,300,000 shares. Based on an average daily volume of 563,600 shares, the days-to-cover ratio is presently 5.5 days. Currently, 13.4% of the company's stock are short sold. View Polarityte's Current Options Chain.

Who are some of Polarityte's key competitors?

What other stocks do shareholders of Polarityte own?

Who are Polarityte's key executives?

Polarityte's management team includes the following people:
  • Mr. David B. Seaburg, Chief Exec. Officer (Age 50, Pay $7.5k)
  • Dr. Edward Winslow Swanson, Chief Translational Medicine Officer & Co-Founder (Age 35, Pay $400k)
  • Mr. Paul Elliot Mann, Exec. Officer
  • Mr. Richard Hague, Pres & COO (Age 60)
  • Mr. Jacob Alexander Patterson, Interim Chief Financial Officer

What is Polarityte's stock symbol?

Polarityte trades on the NASDAQ under the ticker symbol "PTE."

Who are Polarityte's major shareholders?

Polarityte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.30%), Sabby Management LLC (0.91%), State Street Corp (0.82%), Geode Capital Management LLC (0.81%), Advisor Group Holdings Inc. (0.50%) and Levin Capital Strategies L.P. (0.40%). Company insiders that own Polarityte stock include Cameron J Hoyler, David B Seaburg, Denver Lough, Edward Winslow Swanson, Paul Elliot Mann, Peter A Cohen, Rainer M Erdtmann, Richard Hague and Steve Gorlin. View institutional ownership trends for Polarityte.

Which institutional investors are buying Polarityte stock?

PTE stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, Advisor Group Holdings Inc., BlackRock Inc., State Street Corp, Geode Capital Management LLC, Levin Capital Strategies L.P., LWS Wealth Advisors Inc., and Capital Wealth Alliance LLC. Company insiders that have bought Polarityte stock in the last two years include Edward Winslow Swanson, Paul Elliot Mann, Peter A Cohen, and Rainer M Erdtmann. View insider buying and selling activity for Polarityte.

How do I buy shares of Polarityte?

Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Polarityte's stock price today?

One share of PTE stock can currently be purchased for approximately $0.98.

How big of a company is Polarityte?

Polarityte has a market capitalization of $37.55 million and generates $5.65 million in revenue each year. The company earns $-92,490,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Polarityte employs 153 workers across the globe.

What is Polarityte's official website?

The official website for Polarityte is www.polarityte.com.

How can I contact Polarityte?

Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.